Outcomes for metastatic triple-negative breast cancer patients treated with sacituzumab govitecan in clinical studies and real-world studies: a single-arm meta-analysis

Key Points

• Overall survival increased in patients treated with sacituzumab govitecan, indicating potential benefits.
• The analysis included data from multiple clinical studies and real-world studies to strengthen findings.
• Utilizing single-arm meta-analysis, the study highlighted patient outcomes across various treatment settings.
• This research emphasizes the need for continued evaluation of therapies for advanced breast cancer.